By Josh Beckerman Sesen Bio Inc. shares rose 23% to $4.97. The company has said several times that it believes it is on track for a U.S. Food and Drug Administration decision on Vicineum. | August 13, 2021
NYON, Switzerland, Aug. 13, 2021 /PRNewswire/ MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with SELUTION SLR 018 DEB (drug-eluting balloon) for